# TPST-4003

Source: https://onco.cc/drugs/tpst-4003/  
OnCo record `tpst-4003` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

TPST-4003 is a treatment from Tempest Therapeutics meant to turn a patient's T cells into cancer-hunting CAR-T cells inside the body, aimed at two markers on B cells and plasma cells.

## Summary

TPST-4003 is Tempest Therapeutics' lead programme, a dual CD19 and BCMA in vivo CAR-T candidate that Tempest is developing for indications in immunology and oncology. The August 2026 registration statement does not state its stage.

## Fields

- Kind: Treatment
- Last checked: 2026-11-04
- Tags: pipeline
- Code: TPST-4003
- Modality: In vivo CAR-T (dual CD19 and BCMA)
- Mechanism: A dual-targeting CD19 and BCMA chimeric antigen receptor generated in the patient's own T cells inside the body, as described by Tempest Therapeutics.

## Sources

- SEC: Tempest Therapeutics Form S-1, August 2026: https://www.sec.gov/Archives/edgar/data/1544227/000119312526361240/d181522ds1.htm

## Connected records

- technologies: [In vivo CAR-T](https://onco.cc/technologies/in-vivo-car-t/)
- targets: [BCMA](https://onco.cc/targets/bcma/), [CD19](https://onco.cc/targets/cd19/)
- companies: [Tempest Therapeutics](https://onco.cc/companies/tempest-therapeutics/)

---
JSON: https://onco.cc/api/v1/entities/tpst-4003.json